Illaa Smesseim

Ms. Illaa Smesseim


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2021 in Chest
Verified
Journal Article
Open access
MBMarielle M.J. Blacha
Marielle M.J. Blacha
ISIllaa Smesseim
Illaa Smesseim
ILIvo van der Lee
Ivo van der Lee
JAJoost G. van Den Aardweg
Joost G. van Den Aardweg
MSMarcus J. Schultz
Marcus J. Schultz
RLRichard W. Light
Richard W. Light
The "buffalo chest" is a condition in which a simultaneous bilateral pneumothorax occurs due to a communication of both pleural cavities caused by an iatrogenic or idiopathic fenestration of the mediastinum. This rare condition is known by many clinicians because of a particular anecdote which stated that Native Americans could kill a North American bison with a single arrow in the chest by creating a simultaneous bilateral pneumothorax, due to the animal's peculiar anatomy in which there is one contiguous pleural space due to an incomplete mediastinum. What evidence is there for the existence of buffalo chest? The term "buffalo chest" and its anecdote were first mentioned in a ''personal communication'' by a veterinarian in the Annals of Surgery in 1984. A mixed method research was performed on buffalo chest and its etiology. A total of 47 cases of buffalo chest were identified in humans. This study found that all authors were referring to the article from 1984 or to each other. Evidence was found for interpleural communications in other mammal species, but no literature on the anatomy of the mediastinum of the bison was found. The main reason for this research was fact-checking the origin of the anecdote and search for evidence for the existence of buffalo chest. Autopsies were performed on eight bison, and four indeed were found to have had interpleural communications. We hypothesize that humans can also have interpleural fenestrations, which can be diagnosed when a pneumothorax occurs.

30 December 2022 in The Clinical Respiratory Journal
Verified
Journal Article
Open access
ISIllaa Smesseim
Illaa Smesseim
KMKirsten Mooij‐Kalverda
Kirsten Mooij‐Kalverda
LHLisa Hessels
Lisa Hessels
DKDaniel A. Korevaar
Daniel A. Korevaar
BABurak Atasever
Burak Atasever
HRHerre J. Reesink
Herre J. Reesink
Introduction: High flow nasal cannula (HFNC) reduces the need for intubation in patients with hypoxaemic acute respiratory failure (ARF), but its added value in patients with severe coronavirus disease 2019 (COVID‐19) and a do‐not‐intubate (DNI) order is unknown. We aimed to assess (variables associated with) survival in these patients.Materials and methods: We described a multicentre retrospective observational cohort study in five hospitals in the Netherlands and assessed the survival in COVID‐19 patients with severe acute respiratory failure and a DNI order who were treated with high flow nasal cannula. We also studied variables associated with survival.Results and discussion: One‐third of patients survived after 30 days. Survival was 43.9% in the subgroup of patients with a good WHO performance status and only 16.1% in patients with a poor WHO performance status. Patients who were admitted to the hospital for a longer period prior to HFNC initiation were less likely to survive. HFNC resulted in an increase in ROX values, reflective of improved oxygenation and/or decreased respiratory rate.Conclusion: Our data suggest that a trial of HFNC could be considered to increase chances of survival in patients with ARF due to COVID‐19 pneumonitis and a DNI order, especially in those with a good WHO performance status.

18 February 2023 in Thoracic Cancer
Verified
Journal Article
Open access
ISIllaa Smesseim
Illaa Smesseim
RBRobert A. van Boerdonk
Robert A. van Boerdonk
CDChris Dickhoff
Chris Dickhoff
DHDavid J. Heineman
David J. Heineman
MDMax R. Dahele
Max R. Dahele
HDHans (J. M. A.) Daniels
Hans (J. M. A.) Daniels
Introduction: Pre‐invasive squamous lesions of the central airways can progress into invasive lung cancers. Identifying these high‐risk patients could enable detection of invasive lung cancers at an early stage. In this study, we investigated the value of 18F‐fluorodeoxyglucose (18F‐FDG) positron emission tomography (PET) scans in predicting progression in patients with pre‐invasive squamous endobronchial lesions.Methods: In this retrospective study, patients with pre‐invasive endobronchial lesions, who underwent an 18F‐FDG PET scan at the VU University Medical Center Amsterdam, between January 2000 and December 2016, were included. Autofluorescence bronchoscopy (AFB) was used for tissue sampling and was repeated every 3 months. The minimum and median follow‐up was 3 and 46.5 months. Study endpoints were the occurrence of biopsy proven invasive carcinoma, time‐to‐progression and overall survival (OS).Results: A total number of 40 of 225 patients met the inclusion criteria of which 17 (42.5%) patients had a positive baseline 18F‐FDG PET scan. A total of 13 of 17 (76.5%) developed invasive lung carcinoma during follow‐up, with a median time to progression of 5.0 months (range, 3.0–25.0). In 23 (57.5%) patients with a negative 18F‐FDG PET scan at baseline, 6 (26%) developed lung cancer, with a median time to progression of 34.0 months (range, 14.0–42.0 months, p < 0.002). With a median OS of 56.0 months (range, 9.0–60.0 months) versus 49.0 months (range, 6.0–60.0 months) (p = 0.876) for the 18F‐FDG PET positive and negative groups, respectively.Conclusions: Patients with pre‐invasive endobronchial squamous lesions and a positive baseline 18F‐FDG PET scan were at high‐risk for developing lung carcinoma, highlighting that this patient group requires early radical treatment.

17 March 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
RGRobin Goossen
Robin Goossen
MVMariëlle Verboom
Mariëlle Verboom
MBMariëlle Blacha
Mariëlle Blacha
ISIllaa Smesseim
Illaa Smesseim
LBL Beenen
L Beenen
OIon behalf of the PRoVENT–COVID and PRoAcT–COVID Investigators
on behalf of the PRoVENT–COVID and PRoAcT–COVID Investigators
Subcutaneous emphysema, pneumothorax and pneumomediastinum are well-known complications of invasive ventilation in patients with acute hypoxemic respiratory failure. We determined the incidences of air leaks that were visible on available chest images in a cohort of critically ill patients with acute hypoxemic respiratory failure due to coronavirus disease of 2019 (COVID-19) in a single-center cohort in the Netherlands. A total of 712 chest images from 154 patients were re-evaluated by a multidisciplinary team of independent assessors; there was a median of three (2–5) chest radiographs and a median of one (1–2) chest CT scans per patient. The incidences of subcutaneous emphysema, pneumothoraxes and pneumomediastinum present in 13 patients (8.4%) were 4.5%, 4.5%, and 3.9%. The median first day of the presence of an air leak was 18 (2–21) days after arrival in the ICU and 18 (9–22)days after the start of invasive ventilation. We conclude that the incidence of air leaks was high in this cohort of COVID-19 patients, but it was fairly comparable with what was previously reported in patients with acute hypoxemic respiratory failure in the pre-COVID-19 era.

5 September 2021 in European Respiratory Journal
Verified
Conference Paper
Closed access
ISIllaa Smesseim
Illaa Smesseim
BABurak Atasever
Burak Atasever
LHLisa Hessels
Lisa Hessels
DKDaniel Korevaar
Daniel Korevaar
LBLieuwe Bos
Lieuwe Bos
PBPeter Bonta
Peter Bonta
Introduction: High-flow nasal oxygen (HFNO) therapy for acute hypoxic failure in COVID-19 patients might avoid the need for intubation. Little is known about the outcomes of HFNO in COVID-19 patients with a do-not-intubate (DNI) order. Aims and objectives: To evaluate the survival rate of COVID-19 patients with a DNI order in whom HFNO was initiated for hypoxic failure. Methods: Multicentre, retrospective, observational study in the Netherlands. Inclusion: COVID-19 patients with a DNI order in whom HFNO for hypoxic failure was initiated between March 2020 and January 2021. 30 day post discharge survival rate and variables associated with survival were assessed, including respiratory rate oxygenation (ROX) index. Results: 56 patients were assessed (median age: 78.0 years (IQR 72,0-81,0), 82.1% male). 16 patients (28.6%) were alive 30 days after discharge. Preliminary univariate analysis showed that median days from admission to start HFNO was shorter among survivors vs non-survivors (2.0 (IQR 0.25-3.75) vs 4.0 (1.0-9.0) days; p<0.05), and showed a better median WHO performance score at admission (0.0 (IQR 0.0-1.0) vs 1.0 (0.5-2.0); p<0.05). Median ROX on day 0 was similar in both groups, but significantly lower in the non-survival group from day 2 onwards. ROX diverted between both groups at day 4, with further decline in non-survivors as opposed to an increase in survivors. Conclusion: This is the first study to describe outcomes of HFNO in COVID-19 patients with a DNI order. Survival rates were moderate. Timing of HFNO initiation, WHO performance score, and failure to increase in ROX after 4 days may help in patient selection and feedback towards treatment.